Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

doi:10.1200/JCO.2015.62.4726

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Dec 2015

Grisham Rachel N, Sylvester Brooke E, Won Helen, McDermott Gregory, DeLair Deborah, Ramirez Ricardo, Yao Zhan, Shen Ronglai, Dao Fanny, Bogomolniy Faina, Makker Vicky, Sala Evis, Soumerai Tara E, Hyman David M, Socci Nicholas D, Viale Agnes, Gershenson David M, Farley John, Levine Douglas A, Rosen Neal, Berger Michael F, Spriggs David R, Aghajanian Carol A, Solit David B, Iyer Gopa

Abstract excerpt

PURPOSE: No effective systemic therapy exists for patients with metastatic low-grade serous (LGS) ovarian cancers. BRAF and KRAS mutations are common in serous borderline (SB) and LGS ovarian cancers, and MEK inhibition has been shown to induce tumor regression in a minority of patients; however,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Ovarian Epithelial

Share to Cystadenocarcinoma, Serous

Share to MAP Kinase Kinase 1

Share to Neoplasm Grading

Share to Neoplasms, Glandular and Epithelial

Share to NIH 3T3 Cells

Share to Tumor Stem Cell Assay

Source

Open in PubMed Open full text

Identifiers

PMID: 26324360
DOI: 10.1200/JCO.2015.62.4726
PMCID: PMC4669594

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26324360-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.PMID 26324360Read ↗

Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic VulnerabilitySemantic proximity Read ↗

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic targetSemantic proximity Read ↗

The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.Semantic proximity Read ↗

Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesSemantic proximity Read ↗

Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma.Semantic proximity Read ↗

Integrated genomic and histopathological analysis of low grade serous ovarian carcinoma identifies clinically distinct disease subtypesSemantic proximity Read ↗

Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient.Semantic proximity Read ↗

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.Semantic proximity Read ↗

The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity Read ↗

MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.Semantic proximity Read ↗

Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.